Therapeutic Potential of Cannabinoids in Glaucoma – Hit or Myth? - A Review
Open Access
- 15 November 2024
- journal article
- review article
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 32, 56053
Abstract
Introduction: Glaucoma is a leading cause of irreversible blindness, characterized by elevated intraocular pressure (IOP) that damages the optic nerve. Current treatments mainly focus on reducing IOP, but some patients do not respond adequately to conventional therapies. Cannabinoids, particularly Δ9-tetrahydrocannabinol (Δ9-THC), have been investigated as potential adjunctive treatments for glaucoma. Studies have shown varying effects of cannabinoids on IOP regulation, though their precise mechanisms remain unclear. Aim of Study: This study aims to evaluate the therapeutic potential of cannabinoids in the treatment of glaucoma by examining their effects on IOP, their mechanisms of action, and the risks and benefits associated with their use. Material and methods: A comprehensive literature review of studies on the therapeutic potential of cannabinoids in glaucoma was conducted using the PubMed database. Results and Conclusions: Cannabinoids, especially Δ9-THC, have demonstrated the ability to reduce IOP in both healthy individuals and glaucoma patients. However, the effect is typically short-lived, lasting only 3-4 hours. The efficacy of cannabinoids in reducing IOP is influenced by the method of administration (oral, intravenous, inhalation) and the delivery system used for topical application. Despite some promising results, the use of cannabinoids as a mainstream glaucoma treatment is limited by factors such as the short duration of action, the potential for addiction, and the occurrence of adverse effects like tachycardia, hypotension, and cognitive impairment. Although cannabinoids offer a unique approach to glaucoma management, further research is necessary to address these limitations and determine their long-term therapeutic viability.Keywords
This publication has 48 references indexed in Scilit:
- CB1R, CB2R and TRPV1 expression and modulation in in vivo, animal glaucoma models: A systematic reviewBiomedicine & Pharmacotherapy, 2022
- Cannabinol modulates neuroprotection and intraocular pressure: A potential multi-target therapeutic intervention for glaucomaBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2022
- Cannabis sativaCurrent Biology, 2020
- Positive and Negative Effects of Cannabis and Cannabinoids on HealthClinical Pharmacology & Therapeutics, 2019
- The arguments for and against cannabinoids application in glaucomatous retinopathyBiomedicine & Pharmacotherapy, 2017
- Cannabinoid abuse and addiction: Clinical and preclinical findingsClinical Pharmacology & Therapeutics, 2015
- The Pathophysiology and Treatment of GlaucomaJAMA, 2014
- Endocannabinoids alleviate proinflammatory conditions by modulating innate immune response in muller glia during inflammationGlia, 2012
- Finding of endocannabinoids in human eye tissues: Implications for glaucomaBiochemical and Biophysical Research Communications, 2005
- Cannabinoid Receptor Signaling2005